Drug profile

The FDA adverse-event record for Potassium Supplement

22 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Potassium Supplement. Species, reactions, and outcomes follow.

#1715 of 2,679
by report volume (all drugs)
22
adverse-event reports
18.2%
death-coded share
Cat
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Potassium Supplement ranks #1671 of 2679 by total reports (22). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1671
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Potassium Supplement has 22 reports now versus 22 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Potassium Supplement changes

Signature read: Potassium Supplement's 18.2% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
22
Total Reports
4
Deaths Reported
18.2%
Death-coded share of reports

Active Ingredients

Potassium Supplement

Administration Routes

UnknownOralSubcutaneous

Species Affected

Cat 16
Dog 6

Most Affected Breeds

Domestic Shorthair 12
Domestic Mediumhair 2
Chihuahua 1
Collie - Border 1
Shih Tzu 1
Schipperke 1
Sheepdog (unspecified) 1
Cat (unknown) 1
Retriever - Labrador 1
Maine Coon 1

Most Reported Reactions

Weight loss 4
Lack of efficacy - NOS 4
Behavioural disorder NOS 3
Decreased appetite 3
Urinary incontinence 3
Hypokalaemia 3
Lethargy (see also Central nervous system depression in Neurological) 3
Anorexia 3
Other abnormal test result NOS 2
Vomiting 2
Increased percentage reticulocytes 2
Elevated alanine aminotransferase (ALT) 2

Outcome Breakdown

Ongoing
8 (36.4%)
Recovered/Normal
7 (31.8%)
Outcome Unknown
3 (13.6%)
Died
2 (9.1%)
Euthanized
2 (9.1%)

Potassium Supplement: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Potassium Supplement (#1715 of 2,679 by report volume); death-coded 18.2%. PlainBreed drug row · death-coded share stamp 18.2% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →